AstraZeneca's Victoza (liraglutide) and Rybrevant (mounjaro): While liraglutide is an older GLP-1 RA with lower efficacy, AstraZeneca is also developing its own dual GIP/GLP-1 agent, currently in clinical trials
GHK-Cu creates new vessels while addressing inflammation and signaling
Petersburg Institute of Bioregulation and Gerontology, marketed as a Semax and Selank are two synthetic heptapeptides developed at the same Russian institute, built on the same design trick take a short bioactive fragment of a natural molec SLU-PP-332 is not a peptide
The STEP Trials (Ozempic/Wegovy) In the STEP 1 trial, participants on semaglutide 2.4 mg lost an average of 14.9% of body weight over 68 weeks
The research was conducted by a team from Seoul National University Hospital, including Prof
Global temperatures are climbingbut how is this trend playing out across the United States, and which regions are being hit the hardest